Mark D. Benson

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 342 citations · Full text

Medicine, Nephrology, Pharmacology +13

Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease

Debby Ngo, Sumita Sinha, Dongxiao Shen et al. · Circulation · 2016 · 217 citations · Full text

Medicine, Cardiology, Molecular Medicine +17

Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods

Daniel H. Katz, Jeremy Robbins, Shuliang Deng et al. · Science Advances · 2022 · 207 citations · Full text

Life Sciences, Genetics, Molecular Biology +15

Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered

Stuart McPherson, Julie R. Jonsson, Gary Cowin et al. · Journal of Hepatology · 2009 · 177 citations

Medicine, Pathology, Radiology +12

SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5

Mark D. Benson, Qiu-Ju Li, Katherine Kieckhafer et al. · Proceedings of the National Academy of Sciences · 2007 · 148 citations · Full text

Natural Sciences, Cardiology, Molecular Biology +17